Gestational diabetes mellitus. Diabetes mellitus in pregnancy, unspecified
Conditions
Interventions
Intervention 1: Intervention group will receive 4 oral vitamin D supplement capsules consisting of 50000 IU of vitamin D3 ) 1 every 2 weeks for 8 weeks. Vitamin D supplements will be purchased from th
Treatment - Drugs
Placebo
Intervention group will receive 4 oral vitamin D supplement capsules consisting of 50000 IU of vitamin D3 ) 1 every 2 weeks for 8 weeks. Vitamin D supplements will be purchased from the Zahravi Pharm
The control group received 4 oral placebo (containing paraffin) 1 every 2 weeks for 8 weeks. Vitamin D supplements will be purchased from the Zahravi Pharm Co. All the patients will receive the supple
Sponsors
Vice chancellor for Research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: gestational diabetes; age between 15 and 45 years old and gestational age 24-28 weeks. Exclusion criteria: thyroid and parathyroid disorders, kidney disease, heart disease, hypertension, smoking and usage of nutritional supplements containing vitamin D in the past 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum 25 (OH) vitamin D3. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: chemiluminescence immunoassay system.;Fasting blood glucose. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic colorimetric.;Serum Fasting insulin. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: chemiluminescence immunoassay system.;HbA1C (Glycosilated hemoglobin). Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Chromatography.;Insulin resistance. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: HOMA-IR calculation.;Total cholesterol. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic methods.;Triglycerides. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic methods.;HDL-Cholesterol. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic methods.;High sensivity-C reactive protein. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Nephlometry.;LDL-Cholesterol,. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Freidwald’s formula: LDL-C = TC- HDL-C - (TG/5). | — |
Secondary
| Measure | Time frame |
|---|---|
| Energy and macronutrients intake and vitamin D intake. Timepoint: before and after 8 weeks intervention. Method of measurement: 24-h recall Questionnaire.;Body nass index. Timepoint: before and after 8 weeks intervention. Method of measurement: weight(Kg)/Square Height. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactdoctor Bahram Poor Gaseme Gargari
Tabriz University of Medical Sciences, Faculty of Health and Nutrition
Outcome results
None listed